The combination is considered relevant as part of symptomatic management, providing support that helps ease the overall symptom load for patients during periods of heightened discomfort. Its therapeutic relevance spans conditions where symptoms may intensify temporarily, requiring supportive symptom management across different domains. Specific active components are indicated for the management of acute pain and primary dysmenorrhea.

Relief for Acute Pain and Associated Inflammation

This medication is commonly used across conditions involving recurrent or episodic manifestations, such as primary dysmenorrhea and specific types of acute headache. It is applied in clinical settings that involve acute or unstable symptom patterns, and may assist with discomfort experienced after dental or minor surgical procedures, to help manage pain that is generally accompanied by symptoms related to inflammatory or irritative states.

Support for Systemic Discomfort and Functional Stability

It is applied in addressing symptom clusters that may become intense or disruptive. This formulation is relevant for easing symptoms related to systemic imbalance, which may include elevated body temperature (fever) and generalized body aches. This support assists with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Relief for Acute, Moderate Symptoms
Target Symptom Category	Acute Pain, Localized Inflammation, Associated Fever
Typical Contexts of Use	Episodic Pain, Post-Procedural Discomfort, Flare-ups
Core Benefit	Helps ease the overall symptom burden and supports comfort.

The eligibility for Dorex (Celecoxib, Paracetamol, Caffeine) is strictly defined by regulatory warnings and absolute prohibitions related to its components, primarily the NSAID, Celecoxib.

Absolute Contraindications (Must Not Use)

Contraindicated Condition/Population	Regulatory Basis
Known sulfonamide (sulfa) allergy or known hypersensitivity to any component.	Prohibited (Celecoxib component).
History of asthma, urticaria, or allergic reactions to aspirin or other NSAIDs.	Prohibited (NSAID class restriction).
For pain treatment immediately before or after Coronary Artery Bypass Graft (CABG) surgery.	Prohibited (FDA mandate).
Starting at 30 weeks of gestation (third trimester of pregnancy).	Prohibited (Risk of fetal ductus arteriosus closure).

Restricted and Special Populations

• Pediatric Use: Use is generally not established for the typical acute pain indications of this combination in children and adolescents under 18 years of age.
• Organ Function: Use is not recommended in patients with severe hepatic impairment or severe renal impairment.
• Older Adults: Use requires caution due to increased susceptibility to cardiovascular and gastrointestinal adverse events, limiting use to the lowest effective duration.
• Pregnancy/Lactation: Use should be avoided from 20 weeks of gestation onward. Use while breastfeeding is generally not recommended.

Official Interaction Profile

Dorex, a combination of Celecoxib, Paracetamol, and Caffeine, has documented interactions that arise from its active components, as defined by government regulatory labeling.

Classification	Interacting Agents / Conditions	Regulatory Constraint
Contraindicated Combinations	Other Acetaminophen-containing products	Use is prohibited due to the risk of exceeding the maximum safe daily dose, which can lead to severe liver damage (hepatotoxicity).
	Coronary Artery Bypass Graft (CABG) Surgery	Contraindication for the Celecoxib component in the setting of perioperative pain.
Pharmacodynamic Interactions	Oral Anticoagulants (e.g., Warfarin)	Combination results in a heightened, officially documented risk of serious bleeding and hemorrhage.
	ACE Inhibitors / ARBs / Diuretics	The Celecoxib component may officially diminish the efficacy of these antihypertensive and natriuretic agents.
Metabolic Interactions	CYP2C9 Inhibitors (e.g., Fluconazole)	Co-administration is a documented pharmacokinetic interaction that officially increases the plasma exposure of celecoxib.
	Chronic Heavy Alcohol Use	Explicitly documented interaction that significantly increases the risk of severe liver damage due to the Paracetamol component.

Population-Specific Notes: The official label notes that the risk of deterioration of renal function is heightened when the Celecoxib component is combined with ACE Inhibitors or ARBs in elderly, volume-depleted, or renally impaired patients.

️ Selective Inhibition of Peripheral Inflammatory Enzymes

The mechanism begins with Celecoxib, which acts as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. COX-2 is central to the arachidonic acid cascade that produces inflammatory mediators like PGE2 at sites of tissue damage. By blocking this molecular step, the drug limits the generation of these mediators, which results in decreased local prostaglandin-mediated sensitization of nociceptors.

Central Modulation of Pain and Temperature Regulation

Paracetamol exerts its action primarily within the Central Nervous System (CNS), focusing on the inhibition of prostaglandin synthesis in the brain and spinal cord. This molecular effect modulates the central nociceptive threshold and facilitates the resetting of the hypothalamic set-point, promoting heat dissipation mechanisms.

Complementary Action via Neurotransmitter Receptor Blockade

The inclusion of Caffeine introduces a distinct mechanism by serving as a nonselective antagonist of central adenosine receptors ( A1 and A2A). By blocking this purinergic signaling pathway, which otherwise promotes nociception, Caffeine modulates central inhibitory pathways involved in nociception and contributes an anti-nociceptive mechanism that complements the prostaglandin inhibition pathways.

How Dorex is Used: Official Administration Guidelines

The usage of the Dorex fixed-dose combination (FDC) tablet is determined by clinical administration protocols for its active components. This section describes the general principles of its use, focusing strictly on standardized dosing and administration patterns.

---

Administration Scope

Instruction	Detail
Route of administration	Oral administration only.
Dosing schedule	The regimen follows an Initial Single Loading Dose of the FDC, succeeded by a lower, sustained Maintenance Dose as required.
Timing in relation to meals	May be administered with or without food.
Preparation requirements	The tablet must be swallowed whole (intact) with water; no preparation, crushing, or dilution is required.
Special procedural conditions	Dose reduction is required for patients with moderate hepatic impairment (Child-Pugh Class B).

---

Instruction Classifications

Classification	Detail
Administration method type	Oral (tablet, swallowed intact).
Frequency pattern	Twice daily (BID) for maintenance use, following the initial single dose.
Use-context constraints	The FDC is intended for short-term symptomatic management only.

---

Resulting Procedural Structure

The clinical guidelines establish a sequence beginning with the initial single loading dose of the FDC tablet. If continued management is necessary, the patient then begins the twice-daily (BID) maintenance regimen. This sequence must be followed for the shortest duration consistent with the clinical objective. If a scheduled dose is missed, patients are instructed not to take a double dose to compensate.

Research Evidence for Dorex: Overview of Studies

Research Evidence for Acute Pain and Post-Procedural Relief

The research base exploring the fixed-dose combination (FDC) approach for acute pain includes Randomized Controlled Trials (RCTs) and Systematic Reviews focused on the active components—Celecoxib, Paracetamol, and Caffeine—or similar combinations. This body of evidence was applied in research contexts that examined fluctuating or unstable symptoms, such as pain following minor procedures, including dental extractions or minor surgeries. These studies monitored outcomes related to physical discomfort and changes in patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity examined how symptoms changed over defined time intervals. Research focused on measuring Pain Intensity using standard scales and the patient's need for rescue analgesic medication. Findings describe patterns observed in studies evaluating measurements related to changes in symptom intensity and speed when the agents were compared to inactive treatments. Studies report how symptoms evolved in the observed populations primarily over the immediate short-term period, typically a matter of hours to a few days.

A key uncertainty lies in the direct evidence for this specific three-component formulation. While there is substantial evidence for the component classes, comparative evidence is lacking for large-scale RCTs specifically designed to isolate the unique research profile of this exact FDC against two-component FDCs or its monocomponents across all relevant acute pain types. Research describes the specific conditions under which the studies were conducted: immediate, acute pain management.

---

Studies Addressing Episodic Pain Conditions

The combination was evaluated in research exploring short-term symptom changes associated with conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea and acute headaches. These studies, which include Randomized Controlled Trials and Placebo-Controlled Studies, focused on episodes where symptoms become more noticeable. Research examined outcomes reflecting episodic or acute changes and measures like the time elapsed until a defined cessation of symptoms was reported by the study participants.

Research exploring episodic pain was conducted during periods of increased symptom activity, examining how symptoms changed over defined time intervals. Trials reported how pain evolved during the single acute episode being monitored in the observed populations. These findings describe group patterns and were applied in studies examining patient-reported experiences related to changes in patient-reported outcomes describing perceived discomfort for the most noticeable symptoms.

However, the evidence is primarily derived from settings with varying symptom burdens and is often concentrated on the individual active components. Subgroup findings are uncertain when trying to define the specific additive contribution of the triple combination compared to well-established two-drug options for these episodic conditions. Research focused on short-term changes during the acute flare-up; however, there is limited information for long-term outcomes related to the overall frequency or pattern of these recurrent conditions.

---

What We Know About Long-Term Studies and Extended Use

The research on this specific fixed-dose combination and its components for acute, episodic use primarily focuses on short-term outcomes. This evidence was applied in trials assessing short-term or episodic symptom patterns, but research does not determine whether an individual will respond similarly when considering long-term use.

There is limited information for long-term outcomes or the consequences of using this combination over extended periods. Research exploring maintenance use or outcomes beyond a few days to a week for acute pain is not well characterized in publicly available regulatory summaries, and certainty remains low regarding long-term or repeated use outcomes.

---

Research in Specific Populations

Research for the components of Dorex primarily included healthy adult participants experiencing acute symptoms. The results apply only to the populations studied, which means the data for certain groups remain insufficient. Studies have focused on adults across various baseline pain severities to characterize the short-term response.

Data for certain groups remain insufficient, and evidence is limited for populations such as children and older adults in the context of this specific FDC. Furthermore, there is a lack of publicly available research and dedicated studies evaluating outcomes in populations with specific comorbidities (other concurrent health conditions) who were not included in the primary trials.

---

Key Uncertainties and Research Gaps

The available evidence highlights what is known—and what is still uncertain—about this combination. A primary research limitation is that comparative evidence is lacking for large-scale, head-to-head studies that confirm the specific research profile of combining all three agents versus using common two-component alternatives for every studied indication.

Additionally, the follow-up durations were limited in most key studies, which means long-term effects are not fully established. Studies focused on short-term changes; however, certainty remains low regarding outcomes after long-term or repeated use. Studies contributed to the broader evidence landscape for how patients reported their experience during a brief, acute episode, but evidence quality varies across studies and across the different components of the FDC.

Common questions about Dorex (FAQ)

---

Q: How long does it typically take to feel an effect from Dorex?

Official pharmacokinetic data for the Celecoxib component show that it reaches its highest levels in the bloodstream approximately 3 hours after a dose. This time frame indicates when the maximum concentration is achieved in the body. The time it takes for an individual to feel relief can vary.

---

Q: Is Dorex safe for people over 65?

Official drug information indicates that older adults are at a greater risk for serious adverse events, including issues affecting the stomach, intestines, and cardiovascular system. Because of this heightened susceptibility, monitoring is often recommended for this population.

---

Q: Does Dorex affect blood pressure?

Regulatory warnings state that the medicine's NSAID component may cause high blood pressure, known as hypertension, or may worsen existing high blood pressure. Monitoring of blood pressure may be recommended by a healthcare professional during treatment.

---

Q: Can Dorex cause vivid dreams or sleep changes?

Insomnia, or sleeplessness, is listed as a common reported effect. Additionally, official post-marketing reports for the Celecoxib component have noted other central nervous system effects, such as anxiety, nervousness, and, rarely, hallucinations.

---

Q: How long does Dorex stay in your system after stopping it?

Regulatory pharmacokinetic data shows that the Celecoxib component has an effective half-life of approximately 11 hours. A drug's half-life is the time it takes for half of the substance to be eliminated from the body. Complete elimination typically involves several half-lives.

---

Q: What are some over-the-counter medicines that interact with Dorex?

Official drug labels advise caution when taking the Celecoxib component alongside other nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin. Combining these types of medications is associated with an increased risk of side effects, particularly those affecting the stomach and intestines.

---

Q: If I have a metallic taste after starting Dorex, is that a known side effect?

A change in the sense of taste, including possible metallic taste, is noted in official documentation as a less common side effect associated with the Celecoxib component. It is not listed among the most frequently reported adverse events.

---

Q: How do I know if Dorex is working for me?

Studies that led to the drug's approval measured its success based on patient-reported outcomes, such as a reduction in pain intensity and a decreased need for supplementary pain medication. A clinical response is generally observed when an individual experiences an improvement in their reported symptoms, such as pain relief.

---

Q: Why is Dorex prescribed for [Disease Area]?

Official documents describe the Celecoxib component as indicated for the treatment of various inflammatory and painful conditions. These can include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea.

---

Q: Does Dorex treat the cause or just the symptoms?

The official mechanism of action involves inhibiting a substance called prostaglandin, which reduces inflammation and pain signals. Based on this mechanism, the drug is primarily described in regulatory documents as a medicine that provides symptomatic relief.

---

Q: What are the signs of a severe allergic reaction to Dorex?

Official safety information describes the need for emergency medical assessment if signs of a severe allergic reaction occur. These signs may include swelling of the face, lips, tongue, or throat, hives, or significant difficulty breathing.

---

Q: Is it normal to feel tired when starting Dorex?

While fatigue or general weakness is not listed as a common or frequently reported side effect, official documents note it as a symptom that can be associated with certain, less common serious adverse reactions.

---

Q: Can Dorex affect my mood or emotional state?

Adverse event reports have included effects on emotional state, such as anxiety, nervousness, and depression. In rare cases, hallucinations have also been observed with the Celecoxib component.

---

Q: Do any herbal supplements or vitamins interact with Dorex?

The official label advises patients to notify their healthcare provider about all substances they are taking, which includes any medications, supplements, herbs, and vitamins. This notification is a way to address potential interactions not explicitly documented in the official drug label.

---

Q: Does the strength of Dorex I take matter for side effects?

Regulatory warnings describe that the potential risk of serious side effects, particularly those affecting the cardiovascular system and the stomach or intestines, is associated with higher doses of the Celecoxib component.

---

Q: What does it mean if Dorex is 'contraindicated' for a certain group of people?

A contraindication is a regulatory decision that the potential risks of the drug significantly outweigh any possible benefits for a specific group of people or under certain conditions. This indicates the medicine is generally excluded from use in those specific circumstances.

---

Q: What does 'potential for liver enzyme elevation' mean for Dorex?

This phrase indicates that laboratory tests may show elevated levels of certain enzymes, which can be a sign of potential stress or injury to the liver. Monitoring of liver function tests is sometimes noted as a recommended precaution in official guidelines.

---

Q: Will Dorex affect my ability to drive or operate machinery?

Regulatory documents state that because side effects like dizziness and drowsiness are reported, awareness of individual response is necessary before driving or operating complex machinery.

---

Q: Can I take Dorex if I have a history of seizures?

While seizures are noted as a rare potential side effect, official information describes a need for caution when the Celecoxib component is considered for patients who have existing nervous system disorders.

---

Q: Does Dorex interact with birth control pills?

Regulatory data suggests that the Celecoxib component may increase the level of estrogen-containing oral contraceptives in the body. The full clinical importance of this specific interaction is not always explicitly documented.

---

Q: Do I need routine blood tests while I am taking Dorex?

Official monitoring guidelines may recommend routine testing of blood pressure, kidney function, liver function, and complete blood counts. Monitoring is often described as being particularly relevant for patients on long-term therapy or those who have existing risk factors.

---

Q: What is the half-life of Dorex?

The effective half-life for the Celecoxib component is approximately 11 hours. Half-life is a measure of the time it takes for the concentration of the medicine in the body to be reduced by half. The Paracetamol and Caffeine components have shorter half-lives.

---

Q: Why does the manufacturer's leaflet warn about sun exposure?

Official adverse event listings for the Celecoxib component include a potential risk of photosensitivity. This means the skin may become unusually sensitive to sunlight, increasing the risk of severe sunburn.

---

Q: Is Dorex suitable for people with diabetes?

Official information lists diabetes as a risk factor for cardiovascular problems. Close monitoring may be recommended when the Celecoxib component is used in patients with this condition, due to safety considerations regarding heart-related events.

---

Q: Does taking Dorex cause weight gain or loss?

Weight changes are not commonly listed as a standard side effect. However, weight gain is noted in official documents as a symptom that can occur in cases of fluid retention or overdose.

---

Q: What is the primary way Dorex is eliminated from the body?

Regulatory pharmacokinetic data indicates that the Celecoxib component is primarily processed (metabolized) in the liver. The resulting substances are then mainly eliminated from the body through the feces and urine.

---

Q: Are there any specific genetic factors that influence how Dorex works?

Yes, official labeling includes pharmacogenetic information. The Celecoxib component is metabolized by a liver enzyme called CYP2C9. Regulatory guidance includes information that patients who are known to have reduced function of this enzyme are a group for whom a dose adjustment may be necessary.

Storage and Disposal Requirements

Official regulatory guidelines for the components of Dorex (Celecoxib, Paracetamol, Caffeine) mandate specific conditions to ensure product stability and public safety.

Storage Scope	Requirement
Temperature	Store below 30 C (86 F) at controlled room temperature, and keep from freezing.
Protection	Store in the original container, tightly closed, and protect from light, heat, and moisture.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.
Disposal	Do not keep outdated medicine. Dispose of unused or expired product according to local regulations, often by returning it to a pharmacy or using official drug take-back programs.

The official labeling defines these constraints to preserve the medicine's integrity. Disposal must follow authorized methods to ensure compliance with environmental and health standards.